Zacks Investment Research cut shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a report published on Friday.

According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “

Other research analysts have also recently issued reports about the company. Seaport Global Securities assumed coverage on Omeros in a research report on Thursday, July 12th. They set a buy rating and a $30.00 price target for the company. HC Wainwright set a $34.00 price target on Omeros and gave the company a buy rating in a research report on Monday, August 6th. Maxim Group reiterated a buy rating and set a $25.00 price target on shares of Omeros in a research report on Monday, May 7th. ValuEngine upgraded Omeros from a hold rating to a buy rating in a research report on Saturday, May 12th. Finally, Wedbush reiterated a hold rating and set a $20.00 price target (up from $19.00) on shares of Omeros in a research report on Wednesday, May 16th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. Omeros presently has an average rating of Hold and an average target price of $27.56.

Shares of OMER stock opened at $19.18 on Friday. The company has a debt-to-equity ratio of -2.91, a current ratio of 3.19 and a quick ratio of 3.18. The company has a market cap of $856.23 million, a P/E ratio of -24.08 and a beta of 3.76. Omeros has a twelve month low of $8.36 and a twelve month high of $25.20.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.04). The company had revenue of $1.70 million during the quarter, compared to the consensus estimate of $1.84 million. The company’s quarterly revenue was down 90.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.33) EPS. equities analysts predict that Omeros will post -2.45 earnings per share for the current year.

In other Omeros news, VP Marcia S. Kelbon sold 4,277 shares of the firm’s stock in a transaction that occurred on Thursday, July 12th. The stock was sold at an average price of $21.48, for a total value of $91,869.96. Following the sale, the vice president now directly owns 188,922 shares of the company’s stock, valued at $4,058,044.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Marcia S. Kelbon sold 40,723 shares of the firm’s stock in a transaction that occurred on Friday, July 27th. The shares were sold at an average price of $21.56, for a total value of $877,987.88. Following the completion of the sale, the vice president now directly owns 219,645 shares in the company, valued at $4,735,546.20. The disclosure for this sale can be found here. 12.10% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of OMER. Capital Impact Advisors LLC acquired a new stake in Omeros in the second quarter valued at approximately $1,749,000. Ingalls & Snyder LLC grew its holdings in Omeros by 1.3% in the second quarter. Ingalls & Snyder LLC now owns 5,613,487 shares of the biopharmaceutical company’s stock valued at $101,829,000 after purchasing an additional 70,625 shares during the period. Alps Advisors Inc. acquired a new stake in Omeros in the second quarter valued at approximately $1,271,000. Nisa Investment Advisors LLC acquired a new stake in Omeros in the second quarter valued at approximately $1,099,000. Finally, Deutsche Bank AG grew its holdings in Omeros by 120.8% in the fourth quarter. Deutsche Bank AG now owns 105,909 shares of the biopharmaceutical company’s stock valued at $2,057,000 after purchasing an additional 57,945 shares during the period. 45.94% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Further Reading: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on Omeros (OMER)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.